- Home
- AVD vs AGEN Comparison
AVD vs AGEN Comparison
Compare AVD & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVD | AGEN |
|---|---|---|
| Founded | 1969 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.6M | 126.8M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | AVD | AGEN |
|---|---|---|
| Price | $4.31 | $3.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $12.00 | ★ $14.50 |
| AVG Volume (30 Days) | 182.6K | ★ 450.4K |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $530,073,000.00 | $106,829,000.00 |
| Revenue This Year | N/A | $67.15 |
| Revenue Next Year | $3.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.28 | $1.38 |
| 52 Week High | $6.33 | $7.34 |
Technical Indicators
Market Signals| Indicator | AVD | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 41.43 | 38.61 |
| Support Level | $4.12 | $3.82 |
| Resistance Level | $4.48 | $4.12 |
| Average True Range (ATR) | 0.19 | 0.20 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 30.36 | 0.58 |
Price Performance
Historical ComparisonAbout AVD American Vanguard Corporation ($0.10 Par Value)
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. It manufactures and formulates chemicals for crops, turf and ornamental plants, and human and animal health protection. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).